Submission Details
| 510(k) Number | K173861 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | December 20, 2017 |
| Decision Date | May 02, 2018 |
| Days to Decision | 133 days |
| Submission Type | Traditional |
| Review Panel | Neurology (NE) |
| Summary | Summary PDF |
K173861 is an FDA 510(k) clearance for the Drug Relief, a Percutaneous Nerve Stimulator For Opioid Withdrawal (Class II — Special Controls, product code PZR), submitted by Dyansys, Inc. (San Mateo, US). The FDA issued a Cleared decision on May 2, 2018, 133 days after receiving the submission on December 20, 2017. This device falls under the Neurology review panel. Regulated under 21 CFR 882.5896.
| 510(k) Number | K173861 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | December 20, 2017 |
| Decision Date | May 02, 2018 |
| Days to Decision | 133 days |
| Submission Type | Traditional |
| Review Panel | Neurology (NE) |
| Summary | Summary PDF |
| Product Code | PZR — Percutaneous Nerve Stimulator For Opioid Withdrawal |
| Device Class | Class II — Special Controls |
| CFR Regulation | 21 CFR 882.5896 |
| Definition | Stimulate Nerve Branches To Aid In The Reduction Of Symptoms Associated With Substance Use Disorders. |